Mesoblast Ltd
ASX:MSB

Watchlist Manager
Mesoblast Ltd Logo
Mesoblast Ltd
ASX:MSB
Watchlist
Price: 2.63 AUD 2.73%
Market Cap: 3B AUD
Have any thoughts about
Mesoblast Ltd?
Write Note

Wall Street
Price Targets

MSB Price Targets Summary
Mesoblast Ltd

Wall Street analysts forecast MSB stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MSB is 1.75 AUD with a low forecast of 1.11 AUD and a high forecast of 2.74 AUD.

Lowest
Price Target
1.11 AUD
58% Downside
Average
Price Target
1.75 AUD
34% Downside
Highest
Price Target
2.74 AUD
4% Upside
Mesoblast Ltd Competitors:
Price Targets
PAR
Paradigm Biopharmaceuticals Ltd
115% Upside
NANO
Nanobiotix SA
282% Upside
BIIB
Biogen Inc
63% Upside
2162
KeyMed Biosciences Inc
91% Upside
NTRA
Natera Inc
15% Upside
GLPG
Galapagos NV
32% Upside
ZYME
Zymeworks Inc
46% Upside
ALRN
Aileron Therapeutics Inc
671% Upside

Revenue
Forecast

Revenue Estimate
Mesoblast Ltd

For the last 8 years the compound annual growth rate for Mesoblast Ltd's revenue is -22%. The projected CAGR for the next 3 years is 330%.

-22%
Past Growth
330%
Estimated Growth
Estimates Accuracy
-11%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Mesoblast Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-14%
Average Miss

Net Income
Forecast

Net Income Estimate
Mesoblast Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MSB's stock price target?
Price Target
1.75 AUD

According to Wall Street analysts, the average 1-year price target for MSB is 1.75 AUD with a low forecast of 1.11 AUD and a high forecast of 2.74 AUD.

What is Mesoblast Ltd's Revenue forecast?
Projected CAGR
330%

For the last 8 years the compound annual growth rate for Mesoblast Ltd's revenue is -22%. The projected CAGR for the next 3 years is 330%.

Back to Top